• Home Study Details

  • Home / Learn / Home Study CE / Home Study Details


But I Don't Dispense Those! A Community Pharmacist's Guide to Immuno-Oncology Agents

Program Type

OnDemand

Credits

1.5 Contact Hour(s)

Release Date

Monday, December 31, 2018

Offline Date:

Monday, July 15, 2019

ACPE Expiration Date

Friday, July 16, 2021

Target Audience

Nurse, Pharmacist

Cost

$0.00

  • Overview

    The promise of the immune system in helping to treat cancer has finally become a reality in the past few years. The immune system is designed to differentiate between normal cells  foreign cells.  To do this, it uses “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to start an immune response.  Cancer cells often may look like normal cells and may evade the immune system recognition.  An important molecule in this process is CTLA4 and thus a CTLA4 antagonist has been developed to help T cells recognize cancer cells better.  Once the T cells finds the cancer cell another checkpoint is the molecule PD-1 on the T cell which binds to the PD-L1 receptor on the Cancer cell which will cause destruction of the T cell.  This appears to be a major reason why T cells have difficulty killing cancer cells.  Both PD-1 and PD-L1 inhibitors have now been established and have good effects in a variety of cancers including melanoma of the skin, non-small cell lung cancer, kidney cancer, bladder cancer, head and neck cancers,  Hodgkin lymphoma, bladder cancer, non-small cell lung cancer, and Merkel cell skin cancer.

    Since these drugs inhibit normal checkpoints the problem is they may allow T cells to now recognize normal cells as being foreign, which can lead to serious side effects commonly behaving as autoimmune disease.

    The newest agents in the immunology-oncology field are Chimeric Antigen Receptor T cells, in which the patients own T cells are genetically modified to produce a receptor for a target on the T cell.  Currently approved agents express CD19 and are approved for relapsed/refractory ALL and DLBCL.  These are extremely exciting agents which may have the potential for long term remission of cancer.  One problem is if the T cells expand too rapidly they release cytokines, called “Cytokine Storm” which can be life threatening. Thus it is critical pharmacists have a good understanding of the mechanisms and adverse events associated with all of these therapies and a good understanding of how to manage the side effects.


    Handouts

    Slide Document:   18099H01_4pp.pdf
    Slide Document:   18099H01_2pp.pdf

    Financial Support By

    Merck & Co., Inc
  • Nurse

    Identify current FDA approved PD-1, PD-L1 and CTLA4 Inhibitors as well as Chimeric Antigen T cells and their indications and their place in therapy.
    Describe the mechanism of action of these immunologic agents
    Describe the symptoms of the adverse events of these agents and potential management strategies
    Understand the pharmacist's role in communicating recommendations in caring for patients on these agents


    Pharmacist

    Identify current FDA approved PD-1, PD-L1 and CTLA4 Inhibitors as well as Chimeric Antigen T cells and their indications and their place in therapy.
    Describe the mechanism of action of these immunologic agents
    Describe the symptoms of the adverse events of these agents and potential management strategies
    Understand the pharmacist's role in communicating recommendations in caring for patients on these agents

  • Activity Type

    Application

    Universal Activity Number

    Nurse 0798-0000-18-099-H01-P

    Pharmacist 0798-0000-18-099-H01-P

    ACPE PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

    In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

  • Faculty

    David Frame, PharmD
    Assistant Professor, University of Michigan College of Pharmacy




HARDWARE REQUIREMENTS
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
 


SOFTWARE REQUIREMENTS
Microsoft Edge
Internet Explorer 8.0 or higher
Google Chrome
Safari
Firefox 3.0.3 or higher


NETWORK REQUIREMENTS
Broadband Internet Connection:
T1, Hi-speed DSL or Cable
4G cellular connection
 
 

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

 

©2015 PharmCon, lnc. All Rights Reserved | Terms & Conditions | Privacy PolicyContinuing Education For Healthcare Professionals
Developed By: ITB, Inc.